Last updated on November 2017

A study to evaluate the safety and efficacy of an oral investigational drug in individuals who are asymptomatic and at-risk for Alzheimer's disease.

Brief description of study

The primary objective of this study is to determine whether treatment with an oral investigational drug can slow cognitive decline compared with placebo treatment in individuals who are asymptomatic but at high risk for Alzheimer's disease. Asymptomatic means that the individual is not currently experiencing any symptoms of memory loss or cognitive impairment. Individuals may be classified as high-risk by age, having a first-degree relative with Alzheimer's disease, or testing positive for amyloid-beta protein. The study will last approximately 4.5 years.

Eligibility Criteria:
-Attend study visits at Sharp Mesa Vista Hospital's Clinical Research Center
-Have a caregiver (spouse, relative or health care aide) who can accompany you to study visits and help monitor your study progress
-Be 60 to 85 years of age

Clinical Study Identifier: TX133506

Contact Investigators or Research Sites near you

Start Over

Sharp Mesa Vista Hospital Clinical ...

Sharp Mesa Vista Hospital Clinical Research Center
San Diego, CA USA
  Connect »